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have been shown to be potentially 
valid instruments for a number of 
medications including smoking 
cessation therapies.5,8,9 With use of 
instrumental variable methods we have 
identified no evidence that patients 
prescribed varenicline had a decreased 
risk of depression, self-harm, or death 
compared with those prescribed 
nicotine replacement therapy.4 This 
suggests that the reductions in the risk 
of outcomes suggested by conventional 
analyses in the observational studies,2,5 
including the large protective eff ect on 
all-cause mortality, are likely to be due 
to residual confounding. 
We broadly agree with Kotz and 
colleagues’ conclusions regarding the 
safety of varenicline. The results from 
the Food and Drug Administration’s 
adverse Event Reporting System 
database, which suggested patients 
prescribed varenicline have an 
increased risk of depression and 
suicidal behaviour, are likely to be 
biased by residual confounding.10 
Regulators such as the Food and 
Drug Administration have used this 
evidence to justify imposing safety 
warnings on varenicline, but these 
safety warnings are increasingly 
inconsistent with evidence from 
several sources. Research into the 
safety of varenicline should use robust 
methods to try to overcome problems 
of bias. Epidemiologists are acutely 
aware that large observational studies 
can produce very precise, but very 
biased evidence,1 but the public and 
policy makers might not be.
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patients prescribed varenicline were 
at lower risk of depression and self-
harm. Additionally, our observational 
study5 found that patients prescribed 
varenicline had substantially lower 
mortality compared with patients 
prescribed nicotine replacement 
therapy. By contrast, the meta-analysis 
of randomised controlled trials4 
identifi ed little evidence that patients 
prescribed varenicline were less likely 
to be depressed, self-harm, or to die. If 
the adjusted observational results are 
biased for depression and self-harm, it 
is probable that they are biased for the 
other outcomes as well.
We can only interpret Kotz and 
colleagues’ results as unbiased 
estimates of the causal effects of 
varenicline if we assume that there 
are no unmeasured confounders. This 
assumption is unlikely to hold. While 
Kotz and colleagues present the results 
of a simulation of the effects of a 
single unmeasured binary confounder, 
the true confounding structure is likely 
to be much more complex, involving 
multiple clustered confounders, which 
could produce the observed results 
with far smaller eff ects than assumed 
in the simulation.
Observational studies can only 
produce credible evidence of the causal 
eff ects of an exposure if they propose 
a robust method of overcoming 
residual or unmeasured confounding. 
One such approach is instrumental 
variable analysis, which attempts 
to mimic randomisation and allows 
equal distribution of measured and 
unmeasured confounders.6 It relies 
on the availability of an instrument 
that is associated with the exposure, is 
not associated with the confounding 
factors, and has no direct effect on 
the outcome of interest. In their 
published protocol7 Kotz and colleagues 
proposed the use of an instrumental 
variable analysis, but did not include 
this in their final report because of 
the difficulty in identifying valid 
instruments. Physicians’ prescribing 
preferences, identified on the basis 
of physicians’ previous prescriptions, 
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In their letter, Foluke Odeyale and 
Itoro Udo make two points with 
respect to our investigation into the 
cardiovascular and neuropsychiatric 
risks of varenicline for smoking 
cessation.1 First, they mention that 
we did not consider neuropsychiatric 
events such as anxiety, agitation, 
psychosis, and suicidal ideation. 
This is because we were only able 
to include events that are routinely 
recorded by general practitioners in 
the UK. We addressed this limitation 
in the discussion section of our 
Article. That said, it is important to 
emphasise the point that we found 
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trials and so becomes a powerful 
method to overcome unmeasured 
confounding. In practice, however, it 
is generally very diffi  cult to identify 
a valid and strong instrumental 
variable. Providers of health-care 
databases that are used for research 
should therefore consider preparing 
their data in such a way that they 
fit the purpose of an instrumental 
variable analysis and ideally help with 
identifying instrumental variables for 
a particular study.
We were not able to identify an 
instrumental variable for our study 
so, instead, we modelled—for the fi rst 
time in this context—what the eff ect 
and distribution of any potential 
unmeasured confounders needed 
to be to reverse our fi ndings and to 
show an increased risk associated 
with varenicline use. With this 
modelling, we were able to show 
that an increased risk of any of the 
neuropsychiatric and cardiovascular 
events assessed in varenicline users 
was very unlikely. 
Reassuringly,  in their  own 
observational study into the risk of 
depression, suicide, and self-harm 
in varenicline users, Davies and 
colleagues identified no difference 
between the conventional regression 
modelling and the instrumental 
variable analysis, and came to 
the same conclusion as we did.8 
Taken together, we hope that these 
carefully undertaken, large-scale 
observational studies1,8 will lead 
decision makers—such as the US 
Food and Drug Administration—to 
review their safety warnings for 
varenicline. 
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no evidence to indicate an increased 
risk of depression and self-harm, 
which have been identified as among 
the most important serious adverse 
events and are included in the US 
Food and Drug Administration’s black 
box warning for varenicline.
Second, Odeyale and Udo suggest 
that we should have included 
“previous secondary mental health 
care and admission” as a potential 
confounder in our analyses. We would 
like to make two points in response. 
What they speculate about is not 
an example of confounding, but a 
potential interaction between the use 
of varenicline and previous secondary 
mental health-care treatment. The 
purpose of our study, however, was 
to investigate the risks of varenicline 
in the general population of smokers 
rather than in a specific subgroup. 
Therefore, our large, non-restrictive 
sample included smokers with 
previous mental illness. Also, we 
did include key markers of mental 
illness as confounding variables and, 
uniquely, modelled what would need 
to be the distribution and effect 
of any unmeasured confounders 
to invalidate our key conclusions. 
We showed that such confounders 
would only lead to an increased risk 
associated with varenicline use under 
very unlikely assumptions. 
In another correspondence, Johannes 
Nielen and Andrea Burden comment 
on our finding that patients with a 
prescription of nicotine replacement 
therapy showed a higher prevalence 
of previous cardiovascular and 
neuropsychiatric  events than 
patients with a prescription of 
varenicline or bupropion. They offer 
the same explanation as we did in the 
discussion section of our Article1—ie, 
that health-care professionals seem 
less likely to prescribe varenicline and 
bupropion to patients with smoking-
related illnesses.
Our interesting and important 
finding was only made possible by 
using “real-world” observational 
data from one of the largest general 
practice databases in the world. 
An advantage of such data is the 
high generalisability of findings 
because—contrary to randomised 
controlled trials—all  patients, 
including those with pre-existing 
cardiovascular and neuropsychiatric 
disease and co-morbidities, are 
included. Such patients, however, 
seem to be more likely to receive a 
prescription of nicotine replacement 
therapy. In our statistical analyses, 
we therefore  used adjusted 
multivariable regression modelling 
and propensity score analysis to 
account for confounding due to 
these differences. Details about 
propensity score analysis are 
provided in the Article’s appendix 
and our published protocol.1,2 We 
agree with Nielen and Burden that 
these two methods cannot fully 
account for residual confounding; 
however, the authors seem to have 
missed the fact that we additionally 
modelled potential unmeasured 
confounders and were able to show 
that an increased risk of any of the 
neuropsychiatric and cardiovascular 
events assessed in varenicline users 
was very unlikely. On the basis of our 
extensive analyses and the evidence 
from several other studies,3–7 we are 
assured that our key conclusions are 
correct.
Furthermore, we agree with the 
general point made by Davies and 
colleagues that research on the safety 
of varenicline that uses observational 
data should use robust methods 
to account for confounding. In 
our retrospective cohort study,1 
we therefore used multivariable 
regression modelling with adjustment 
for an extensive list of potential 
confounders and propensity score 
analysis. 
Instrumental variable analysis was 
a third analytical approach we had 
planned, as stated in our published 
protocol.2 In theory, an instrumental 
variable resembles the tossing 
of a coin to assign patients to a 
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Use of FEV1 as a measure 
of lung health in the UK 
BiLEVE study 
We read with interest the Article by 
Louise Wain and colleagues,1 but we 
were puzzled by the choice of FEV1 as 
the respiratory outcome to represent 
lung health. FEV1 in isolation is rarely 
used as a clinical measurement 
because it is aff ected by many factors 
unrelated to pulmonary function, 
such as eff ort and total lung volume. 
Although the authors attempted to 
account for some of these factors 
by calculating a “predicted FEV1” for 
bands of age and sex, regressing FEV1 
by height, and defi ning the reference 
group as healthy never-smokers, the 
usual practice, in interpretation of 
pulmonary function, is to examine 
the ratio of FEV1 to FVC.  Without FVC 
data, it is diffi  cult to know whether 
the “high FEV1” group really does have 
normal lung function.  
The use of a non-standard 
measurement of pulmonary function 
when standard measures are readily 
available is especially puzzling because 
the authors apparently have access to 
FVC measurements in their participants. 
These issues are further amplifi ed by 
the absence of information about how 
the lung volumes were measured, 
how the equipment was standardised 
and calibrated, and by the absence of 
absolute values.  
The very small amount of variance 
(4%) accounted for either by the 
previously identified (2%) or by 
the newly identified (1%)  genetic 
variants seems to be within the 
ranges of test-retest values and 
calibration measurements of even 
the best pulmonary function 
laboratories. The small fraction of 
the variance explained by the new 
variants, in concert with the method 
considerations mentioned, only serve 
to fuel skepticism about the often 
promised ultimate clinical usefulness 
of large scale sequencing efforts for 
common diseases.
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 Authors’ reply
We thank David Warner and 
colleagues for their interest in the 
UK BiLEVE1 study and note their 
concerns regarding FEV1. In this 
study, we used FEV1 because it is 
of clinical and epidemiological 
relevance; % predicted FEV1 is used 
to grade COPD severity2 and FEV1 
is a major predictor of all-cause 
mortality, even in lifelong non-
smokers.3,4 The method of lung 
function measurement is described 
in the methods and appendix of 
our Article; further equipment and 
calibration details are available on 
the UK Biobank website (via Field IDs 
3062 and 3063;). Both FEV1 and FVC 
measurements were used to refine 
the sampling frame to individuals 
with spirometry measures which met 
strict ATS/ERS quality guidelines. We 
provide absolute FEV1 values in table 1 
of our Article, and absolute FEV1/FVC 
values in the appendix for individuals 
with COPD and controls.
All six of the signals associated with 
the extremes of FEV1 that we report 
also show association with COPD 
(GOLD stage 2–4, defi ned using FEV1 
and FEV1/FVC); COPD association 
results are shown in table 1 of our 
Article. Warner and colleagues suggest 
that the signals we report could be 
attributed to measurement error. Any 
residual measurement error after the 
stringent quality control measures 
we describe would be expected to 
attenuate estimates towards the 
null, not to generate false-positive 
associations. Furthermore, we show 
replication and corroborative evidence 
in support of the signals we report. 
Consistent with other common 
complex traits, the proportion of the 
variance explained by genetic variants 
detected in this and previous studies5 
is modest. Generally, we expect 
